Recent Updates
Recently added Catalysts

Dermacyd Breeze Pocket BR

Phase 3

Hygiene | Small molecule | Other |Sanofi|Last Updated: Dec 19, 2008

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment30
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00793026Dermacyd Breeze Pocket BR (Lactic Acid) - AcceptabilityPHASE3 COMPLETED 30Nov 1, 2008 -Dec 19, 20081 Brazil
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Absence of irritation
Throughout the study
Good acceptability
Throughout the study
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeSUPPORTIVE_CARE
Treatment Arms
ArmTypeDescription
1EXPERIMENTALDermacyd Breeze Pocket BR (Lactic Acid)
Interventions
NameTypeDescription
Dermacyd Breeze Pocket BR (Lactic Acid)DRUGDermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion criteria: * Integral skin test in the region; * To use products of the same category; Exclusion criteria: * Lactation or gestation; * Use of anti-inflammatory, anti-histaminic or immunosuppressant drugs; * Cutaneous disease (local or spread) in the evaluation area; * Pathology which may...

Countries:Brazil
Unlock Eligibility Criteria